Biopharmaceutical drug delivery company Halozyme Therapeutics (NASDAQ:HALO) announced better-than-expected revenue in Q2 CY2026, with sales up 47.7% year on year to $481 million. The company’s full-year revenue guidance of $1.87 billion at the midpoint came in 5.9% above analysts’ estimates. Its non-GAAP profit of $2.28 per share was 25.5% above analysts’ consensus estimates.

Is now the time to buy HALO? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

Halozyme Therapeutics delivered a notably positive second quarter, as evidenced by the strong market reaction and management’s attribution of outperformance to surging royalty revenue and a wave of new collaboration agreements. CEO Helen Torley highlighted that the ENHANZE platform, now underpinning revenue from six different drugs, enabled a record 50% year-over-year royalty growth. The quarter also benefited from sizable milestone payments tied to newly signed licensing deals, with Torley emphasizing, “The ENHANZE value proposition is attracting new partners and additional products from our current partners at a cracking pace.”

Looking ahead, Halozyme’s raised annual guidance is anchored in expectations for continued high growth from both established and newly launched ENHANZE-enabled products, as well as a significant pipeline of future royalty streams. Management pointed to the broadening adoption of subcutaneous formulations—including in emerging areas like antibody drug conjugates (ADCs) and nucleic acids—as a core driver of future performance. CFO Darren Snellgrove underscored the company’s confidence in its asset-light, platform-based model, noting, “We are pleased to raise the guidance for the remainder of the year, driven by increased projected royalty revenues from established products and the new launch products.”

Key Insights from Management’s Remarks

Halozyme’s second quarter was driven by the expansion of its royalty base, a record pace of new partnership deals, and broadening adoption of its core drug delivery technologies across multiple therapeutic areas.

• Diverse royalty streams: Management credited the quarter’s performance to strong uptake across six ENHANZE-enabled products, with notable contributions from newer launches such as Ocrevus Zunovo, Opdivo Qvantig, and Rybrevant FASPRO. This diversification reduced reliance on a single product and strengthened overall revenue durability.
• Milestone-driven collaboration revenue: The company signed four new collaboration and licensing agreements in the quarter (and a fifth in July), expanding both the number of partners and the therapeutic areas addressed. Upfront milestone payments from these deals were a material contributor to the revenue beat.
• Pipeline expansion in new modalities: Halozyme entered the antibody drug conjugate (ADC) and nucleic acid therapeutic markets for the first time, signing agreements that management described as opening “brand-new growth market segments.” These modalities are expected to diversify and extend future royalty streams.
• Ongoing clinical progress: Two new Phase I studies for ENHANZE partner programs began during the quarter, keeping the company on track to have up to 13 ENHANZE development programs by year-end. This expansion is central to the company’s long-term royalty growth strategy.
• Competitive positioning and legal landscape: Management highlighted ongoing litigation to protect intellectual property, particularly against Merck and Alteogen. The company believes its proven track record, large installed safety database, and manufacturing expertise continue to give it a competitive moat.

Drivers of Future Performance

Management expects future performance to be shaped by expanding partner uptake of ENHANZE and Hypercon, growth in new therapeutic segments, and ongoing investment in R&D and manufacturing scale.

• Broader product adoption: Halozyme anticipates growing royalty revenue as more partners launch subcutaneous formulations, particularly in ADCs and nucleic acids. Management noted that the mix of new and existing partners, along with non-exclusive deals, should support a consistent cadence of new agreements and nominations.
• Hypercon as next growth engine: The Hypercon platform is projected to achieve multiple product launches by the early 2030s, with management targeting $1 billion in annual royalties by the mid-2030s. Investments in manufacturing capacity are expected to accelerate Hypercon’s commercial timeline, though details on costs are still being determined.
• Potential headwinds and risks: Management acknowledged uncertainties related to patent litigation outcomes, the competitive landscape (particularly regarding Alteogen), and the execution risks tied to scaling both ENHANZE and Hypercon portfolios. Attrition in the pipeline and timelines for clinical progress are also areas to watch.

Catalysts in Upcoming Quarters

In the coming quarters, the StockStory team will focus on (1) the pace of new ENHANZE and Hypercon partnership agreements and whether these expand further into ADCs and nucleic acids, (2) the ramp-up of royalty revenue contributions from newly launched subcutaneous products, and (3) progress toward clinical milestones, especially the target of 13 ENHANZE development programs by year-end. We will also monitor developments in patent litigation and any updates on manufacturing investments for Hypercon.

Halozyme Therapeutics currently trades at $100.90, up from $85.76 just before the earnings. Is there an opportunity in the stock? Find out in our full research report (it’s free).

High Quality Stocks for All Market Conditions

ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.

Find out which 5 stocks it’s flagging this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,552% between June 2020 and June 2025). Find your next big winner with StockStory today.